Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Ohio committee hears testimony on bill to block manufacturer limits on 340B contract pharmacies
Summary
Proponents told the Ohio House Insurance Committee that manufacturer-imposed limits on contract pharmacies are reducing 340B savings and patient access; witnesses described lost revenue, service closures and rural access problems. Committee held a second hearing; no vote was taken.
Chairman Lambton and members of the Ohio House Insurance Committee heard proponent testimony Oct. 12 on House Bill 276, the Ohio 340B Pharmacy Access Act, a bill that would bar drug manufacturers from imposing shipment or delivery restrictions on medications solely because a provider participates in the federal 340B Drug Pricing Program.
Julie DeRasi King, president and CEO of the Ohio Association of Community Health Centers, told the committee the 340B program allows federally qualified health centers to buy outpatient drugs at a discount and reinvest savings into patient care. "It simply prohibits drug manufacturers from imposing discriminatory restrictions on the shipment or delivery of medications solely because a provider is a 340B grantee," King said, describing the bill as “narrowly tailored” and saying it would cost the state nothing.
Why it matters: Witnesses said manufacturer restrictions on contract pharmacies have already reduced 340B savings for community…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
